期刊文献+

慢性铅接触者肾损害早期监测指标的研究 被引量:12

Early Monitoring Indices for Renal Injury in People Chronically Exposed to Lead
下载PDF
导出
摘要 [目的]估算引起肾功能损害的血铅的基准剂量 (BMD)和基准剂量可信区间下限 (LBMD) ,探索铅接触引起肾损害的生物接触限值。[方法]选择某蓄电池厂的工人135名为铅接触组 ,以机械工人和学生为对照。观察了血铅含量与尿总蛋白 (TP)、尿β2_微球蛋白 ( β2_MG)和尿N_乙酰_β_D_氨基葡萄糖苷酶 (NAG)的关系。用BMDSVersion1.3.1软件的logis tic模型进行基准剂量估算。[结果]引起肾损害的血铅BMD和LBMD分别为299.4~588.7μg/L和253.4~402.3μg/L,引起肾损害血铅LBMD大小依次为TP、β2_MG和NAG。[结论]尿NAG是监测肾功能损害最敏感的指标 。 To estimate benchmark dose(BMD)and the lower confidence limit on the benchmark dose(LBMD)of blood lead(Pb),and explore the biologic exposure limits of lead that may result in renal dysfunction.135workers from one storage battery plant were selected as Pb exposure group while143mechanics and students as the control group.The relationships beˉtween blood Pb content and the urinary excretion of total protein(TP),β 2 _microglubin(β 2 _MG)and N_acetyl_β_ D_glucosamindase(NAG)were observed.The quantal linear logistic regression model in BMDS Version1.3.1was used to calculate BMD and LBMD of blood Pb.The BMD and LBMD of blood Pb for kidney injury indices were from299.4to588.7and from253.4to402.3μg/L,respecˉtively.The LBMD of blood Pb for kidney injury indices was ranged fromhigh to lowas TP,β 2 _MG and NAG.[Conclusion]The urinary NAG activity could be as a sensitive index for monitoring early renal injury.In assessing renal function in workers occupationally exposed to Pb,blood Pb level from250to400μg/L is a warning signal.
出处 《环境与职业医学》 CAS 北大核心 2003年第5期343-345,共3页 Journal of Environmental and Occupational Medicine
基金 山西省自然科学基金项目(编号 :20011064)
关键词 慢性铅接触 肾损害 基准剂量 血铅 尿总蛋白 Β2-MG NAG lead benchmark dose occupational exposure renal function
  • 相关文献

参考文献6

  • 1Crump KS.Calculation of benchmark doses from continuous data[J]. Risk Anal, 1995,15(1):79-89.
  • 2Barnes DG, Daston GP, Evans JS, et al. Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a refreencee dose[J] .Regul Toxicol Pharmacol, 1995,21 (2) :296-306.
  • 3Gaylor D, Ryan L, Krewski D, et al. Procedures for calculating benchmark doses for health risk assessment[J] .Regul Toxicol Pharmacol, 1998, 28(2) : 150-164.
  • 4Mantovani A, Maranghi F, Ricciardi C, et al. Developmental toxicity of carbendazim: Comparison of no-observed-adverse-effect level and benchmark dose approach[J] .Food Chem Toxicol, 1998,36(1) :37-45.
  • 5Rabovsky J, Fowles J, Hill MD, et al. A health risk benchmark for the neurologic effects of styrene: Comparision with NOAEL/LOAEL approach[J] .Risk Anal,2001,21 (1) : 117-126.
  • 6Zhou T, Ross DG, Devito MJ, et al ,Effects of short-term in vivo exposure to polybrominated diphenyl ethers on thyroid hormones and hepatic enzyme activities in weanling rats[J] .Toxicol Sci,2001,61(1) :76-82.

同被引文献207

引证文献12

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部